Canada: Raising Capital And Investing In The Cannabis Industry

Canada's move towards legalization of cannabis in summer of 2018 makes it uniquely positioned, relative to the United States, to be at the forefront of cannabis commerce and a leader in attracting investment in its cannabis industry.

Currently, the majority of equity capital for cannabis businesses in both Canada and the U.S. is being raised by boutique investment banks. While initially investors in the cannabis industry included individuals and a limited number of small venture capital and private equity funds, larger established funds have recently begun to turn their attention towards the industry. Whether venture capital firm, institutional investor or startup, those seeking early-mover benefit in the "green rush" will want to thoroughly assess their investment mandates, regulatory concerns, and other considerations.

Current Legal Landscape

Cannabis Regulation in Canada

In Canada, the production, cultivation, and sale of cannabis for recreational use is currently illegal. However, if strictly for medicinal purposes and under physician prescription, personal cultivation for medical use and the production, cultivation and sale by licensed medical producers is permitted and regulated under Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR).1

Legislative reform to legalize recreational use, cultivation and sale has been progressing since the Liberal Party of Canada promised legalization during the most recent federal election. On April 13, 2017, the Liberal government introduced the first reading of the bill (Bill C-45) to the House of Commons, which proposes to provide legal access to cannabis, and many analysts and news sources report that the legal sale, cultivation and use of recreational cannabis is expected by the summer of 2018.2 3 Despite this expeditious plan, Secretary to the Minister of Justice and head of the legalization effort William Blair indicated on numerous occasions that timelines are merely speculative and that while the government will keep its promise to legalize cannabis, it is committed to taking the time to do it right, citing the need to develop sound regulations and negotiations with the provinces and territories.4 Further, it has been suggested that the federal government decriminalize possession of non-medical cannabis for personal use until such legislation is passed (though in our view this is unlikely to occur).5 The Canadian 2017 budget provided little insight into the proposed legislation or timeline, but stated that in regulating the industry, the government "will take steps to ensure that taxation levels remain effective over time."6

There is a great deal of optimism surrounding the Canadian cannabis industry. According to Bill C-45, licenses issued under the ACMPR will be deemed to be licenses for the production, testing, packaging, labelling, sending, delivery, transportation, sale, possession or disposal of cannabis, including recreational cannabis, issued under the proposed Cannabis Act. Accordingly, many companies are applying for licenses to produce medical cannabis under the ACMPR in an effort to gain a "first-mover" advantage over their unlicensed counterparts.7 However, as of March 2017, Health Canada had only approved approximately 2.6% of applications received under the ACMPR.8

For more detail on cannabis regulation in Canada, including insights from the report issued by the Task Force, please see Torys' related articles:

Cannabis Regulation in the U.S.

Under U.S. federal law, cannabis is a Schedule I drug under the Controlled Substances Act.9 In short, the drug's Schedule I status means cannabis is illegal under U.S. federal law, regardless of conflicting state laws.10 However, in December 2014, the Rohrabacher-Blumenauer amendment was passed in the House of Representatives prohibiting the Department of Justice from spending funds to interfere with the implementation by states of their own laws that authorize the use, distribution, possession, or cultivation of medical cannabis. The amendment is set to expire on September 30, 2017. Since the passing of the Rohrabacher-Blumenauer amendment, the use of both recreational and medicinal cannabis has been legalized in eight states as of the date of this article.11 While President Trump has publicly stated that he will comply with the Rohrabacher-Blumenauer amendment, there is nonetheless great uncertainty surrounding the U.S. cannabis industry due to the lack of a long-term solution to conflicting federal and state laws and previous signaling by the administration of a crackdown on enforcement of federal drug laws.12 If this trend continues, Canadian producers of cannabis products may be well situated to attract capital from local and foreign investors looking to get in on the recreational cannabis industry, which is projected to generate an annual $5 billion in sales, before factoring in ancillary market products and services.13

Raising Capital and Investing in the Cannabis Industry

Traditional Financing

As a result of illegality, access to capital from traditional lenders has been a major challenge for cannabis cultivation operations and other cannabis-related businesses in both the U.S. and Canada. However, given the clear path to legal recreational use in Canada, traditional lenders in Canada have begun making loans to businesses in the cannabis industry and will likely also begin to provide commercial and investment banking services. In the U.S., so long as cannabis remains an illegal substance under federal law, traditional lenders in the U.S. will almost surely stay clear of the cannabis industry unless there is clear guidance in writing that federal authorities will not enforce federal laws in states that have legalized recreational and medicinal cannabis.14 As it currently stands, federal authorities in the U.S. have the power to close a cannabis dispensary and seize its assets notwithstanding that such dispensary may be legal under applicable state law. While Canadian lenders have begun providing financing to cannabis businesses, to the extent that they have significant operations in the U.S., they may be unwilling to provide cannabis businesses with financing or basic banking services so as not to jeopardize their U.S. operations or potentially violate anti-money laundering law.

Private Equity and Venture Capital

For the reasons outlined above, until now the majority of established venture capital and private equity funds have generally been hesitant to invest in the industry. While these funds are beginning to show greater interest and are finding ways to structure around the risks of investing, most cannabis businesses have historically relied on investments by small venture capital, private equity funds and high-net-worth individuals. Smaller funds are willing to assume the risk that their portfolio companies could be subject to changes in regulation in exchange for the value proposition that their portfolio companies will have a head start compared to other companies or will be merged, acquired or partnered with other companies in the supply chain.

Mainstream venture capital and private equity funds looking to invest in the cannabis industry should consider ways to structure cannabis investments to address the concerns of their institutional investors.

Such venture capital and private equity funds will typically invest through fund investment vehicles which are structured like traditional private equity funds and established for the purpose of investing solely in cannabis or cannabis-related businesses.15 A survey of such funds shows that targeted capital commitments currently range from US$25 million to US$125 million with capital being sourced from high-net-worth investors or family offices, often through cannabis specific investment funds.16 Venture capital and private equity funds are using innovative branding and marketing tools to tackle the stigma associated with cannabis to attract investors. These firms should be prepared to address stricter confidentiality requests from investors who may have reputational concerns associated with investing in the cannabis industry.17 A survey of cannabis-sector investment funds shows that investments are being made across numerous verticals within the cannabis industry, including cannabis and related accessories, medical cannabis, technology platforms and software and cannabis information resources.

Some venture capital and private equity funds making equity investments in cannabis businesses will also provide loans, but at relatively high interest rates. In some cases, the loan has been structured as convertible debt allowing the fund to convert the loan into an equity stake in the company at a future date. In the U.S., it should be noted that to the extent a cannabis business' activity violates U.S. federal law, such business has no entitlement to federal bankruptcy protection (even though its operations may be legal under applicable state law), meaning lenders may have difficulty obtaining repayment.

Large mainstream U.S. and Canadian institutional investors, including pension funds and endowments, are among those investors largely evaluating the cannabis industry from the sidelines. While there have been some early-mover institutional investors in this industry, for many others, investments in cannabis may not be consistent with their investment mandates, particularly as it relates to risk tolerance. In addition, it is not uncommon for institutional investors to be prohibited from investing in portfolio companies that derive revenue from activities such as gambling, pornography, tobacco, alcohol or munitions. Institutional investors will generally negotiate excuse rights with respect to investments in portfolio companies that contravene such investment policies, which are typically set out in the side letters that investors negotiate alongside the limited partnership agreement of the fund.

Mainstream venture capital and private equity funds looking to invest in the cannabis industry should assess whether their institutional investors are subject to internal investment policies that would prohibit them from investing in cannabis and consider ways to structure cannabis investments to address the concerns of their institutional investors, including through the use of side letter provisions to address confidentiality, reputational risk and other concerns (and, where necessary, by granting excuse rights).

Public Capital Raises by Established Licensed Producers

Despite the hesitation among certain investor groups, established Canadian licensed producers of medical cannabis are also turning to the public markets to finance operations. These established licensed producers are taking advantage of the increased demand for cannabis investment opportunities and the high valuations associated with the capital raises by licensed producers are likely tied to the expectations that such licensed producers will ultimately enter the recreational market once legalized. These capital raises are typically led by boutique investment banks who have dominated the industry.

Canopy Growth Corp. (TSX:WEED) (Canopy) is the first Canadian marijuana company to surpass the $1 billion market cap. It moved from the TSX Venture Exchange (the TSXV) in July of 2016 and it has received significant attention from investors as one of the first producers to receive official licensing from Health Canada. Demonstrating further momentum, Aphria (TSX:APH), another Canadian licensed producer of cannabis, upgraded from TSXV and joined Canopy on the TSX on March 23, 2017. Moreover, following Aphria's upgrade to the TSX, it announced on April 20, 2017 that it had raised $100 million for funding continued expansion of its production facility, comprised of $75 million in bought equity financing and a $25 million loan from the WFCU Credit Union.


The emerging recreational cannabis industry presents enormous opportunity for venture capital and private equity funds, and more recently, large institutional players, particularly in Canada which is poised to be a leader in cannabis commerce. Those investing in the cannabis industry today have the opportunity to benefit from an early-mover advantage, but at the same time must be ready to properly address the potential regulatory and other risks associated with such investments.


1 Access to Cannabis for Medical Purposes Regulations (2016), SOR/2016-230 ("ACMPR")

2 Bill C-45, An Act respecting cannabis and to amend the Controlled Drugs and Substances act, the Criminal Code and other Acts, 1st Sess., 42nd Parl., 2017. (first reading 13 April 2017)

3 The Canadian Press. "Liberals introduce long-awaited bills to legalize marijuana by July 2018" National Post 13 April, 2017

4 Slerritt, Jen, and Josh Wingrove. "Marijuana Stocks Drop as Trudeau's Pot Czar Says Canada Won't Rush into Legalization." Globe and Mail 7 Mar. 2017; Interview of MP Bill Blair by Don Martin (March 27, 2017) on Power Play, CTV News Channel

5 Powell, Betsy. "Toronto's public health chief wants pot possession decriminalized now." The Star 5 June 2017

6 2017 Federal Budget

7 ACMPR, supra note 1

8 Babad, Michael. "There Won't Be Enough Pot to Go around When It's Legal in Canada." Globe and Mail 30 Nov. 2016

9 Controlled Substances Act (1970), U.S.

10 Cano, Catherine A., and Kathryn J. Russo. "Seven States Pass New Marijuana Laws on Election Day." Jackson Lewis LLP Publications. 16 Nov. 2016

11 Alaska, California, Colorado, Maine, Massachusetts, Nevada, Oregon and Washington


13 Recreational Marijuana - Insights and Opportunities. Rep. Deloitte, Oct. 2016.

14 "Legal pot is still a tough deal for investors." Pharma & Healthcare Monitor Worldwide. 3 November 2016.

15 Benjamin, Jeff, "Asset manager sees gold in grass' starts PE pot fund," Investment News. 25 May 2015.

16 Huddleston, Tom, "Private equity fund raises $100 million for cannabis startups," Fortune. 4 Nov 2016.

17 Frean, Alexandra, "Big-time investors take a deep breath and dive into America's latest growth industry," The Times. 14 May 2016.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions